OBJECTIVE: To describe patients included in the European Mania in Bipolar Longitudinal Evaluation of Medication (EMBLEM) study and to assess and clinically validate the presence of clinical subtypes of patients with acute mania. METHOD: The EMBLEM study is a 2-year prospective, observational study on the treatment and outcome of patients who are treated for a manic or mixed episode. Latent Class Analysis was used to define discrete groups of patients at baseline. RESULTS: Three groups were identified: 'typical mania' (59% of patients); 'psychotic mania' (27%) with more severe mania and presence of psychotic symptoms; and 'dual mania' (13%) with a high proportion of substance abuse. Patient groups differed in age of onset, social functioning and service needs. CONCLUSION: Dual mania represents a distinct and not infrequent subgroup of patients with mania. The exclusion of patients with comorbid substance problems from clinical trials creates a gap in our knowledge on treatment effectiveness.
OBJECTIVE: To describe patients included in the European Mania in Bipolar Longitudinal Evaluation of Medication (EMBLEM) study and to assess and clinically validate the presence of clinical subtypes of patients with acute mania. METHOD: The EMBLEM study is a 2-year prospective, observational study on the treatment and outcome of patients who are treated for a manic or mixed episode. Latent Class Analysis was used to define discrete groups of patients at baseline. RESULTS: Three groups were identified: 'typical mania' (59% of patients); 'psychotic mania' (27%) with more severe mania and presence of psychotic symptoms; and 'dual mania' (13%) with a high proportion of substance abuse. Patient groups differed in age of onset, social functioning and service needs. CONCLUSION: Dual mania represents a distinct and not infrequent subgroup of patients with mania. The exclusion of patients with comorbid substance problems from clinical trials creates a gap in our knowledge on treatment effectiveness.
Authors: Michael Lukasiewicz; Stephanie Gerard; Adeline Besnard; Bruno Falissard; Elena Perrin; Helene Sapin; Mauricio Tohen; Catherine Reed; Jean-Michel Azorin Journal: Int J Methods Psychiatr Res Date: 2013-03-21 Impact factor: 4.035
Authors: Jean-Michel Azorin; Charles L Bowden; Ricardo P Garay; Giulio Perugi; Eduard Vieta; Allan H Young Journal: Neuropsychiatr Dis Treat Date: 2010-03-24 Impact factor: 2.570
Authors: Jessica Dagani; Giulia Signorini; Olav Nielssen; Moira Bani; Adriana Pastore; Giovanni de Girolamo; Matthew Large Journal: Can J Psychiatry Date: 2016-07-11 Impact factor: 4.356
Authors: Trine V Lagerberg; Ole A Andreassen; Petter A Ringen; Akiah O Berg; Sara Larsson; Ingrid Agartz; Kjetil Sundet; Ingrid Melle Journal: BMC Psychiatry Date: 2010-01-27 Impact factor: 3.630